Q4 2024 Metropolis Healthcare Ltd Earnings Call Transcript
Key Points
- Metropolis Healthcare Ltd (BOM:542650) reported an 11% year-on-year growth in Q4 FY24 revenues and a 15% growth in core revenues.
- The company's B2C revenue grew by 20% year-on-year, with a 7% volume growth and a 13% increase in revenue per patient.
- Metropolis Healthcare Ltd (BOM:542650) has successfully expanded its network, adding 24 new labs and over 550 collection centers in the last 12 months.
- The company has zero debt as of March 31, 2024, and a net cash surplus of INR117 crores.
- The company plans to focus on organic growth through new test enhancements, expanding its collection center network, and improving service standards and digital marketing initiatives.
- The diagnostics sector faces significant challenges for new entrants in scaling profitable revenue, which could impact Metropolis Healthcare Ltd (BOM:542650)'s competitive landscape.
- Hospital entrants into the diagnostics segment face structural challenges, such as differential pricing and difficulty in attracting prescriptions from specialized doctors outside the hospital.
- The company plans to reduce its dividend payout from 30-35% to 15-20% of tax for the next couple of years to retain cash for growth opportunities.
- There is a potential risk in the company's aggressive expansion plans, which could lead to short-term EBITDA margin dilution.
- The company faces competitive intensity in the B2B segment, which could impact its pricing strategy and overall profitability.
Ladies and gentlemen, good day and welcome to the Q4 and FY24 earnings conference call of Metropolis Healthcare Limited, hosted by JM Financial.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on date of this call. These statements do not guarantee the future performance of the company, and it may involve risks and uncertainties that are difficult to predict.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Amey Chalke from JM Financial. Thank you, and over to you, sir.
Yeah. Thank you, and good morning, everyone. On behalf of JM Financial, I, Amey Chalke, welcome you all for Metropolis 4Q FY24 earnings call.
With us today, we have the Metropolis senior management team, represented by Ameera Shah, Managing Director; Mr. Surendran Chemmenkotil, CEO; and Mr. Rakesh Agarwal, CFO.
I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
